Article Text

other Versions

PDF
Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis
  1. K SS Steen (k.steen{at}vumc.nl)
  1. VU University medical center, Netherlands
    1. M T Nurmohamed (mt.nurmohamed{at}vumc.nl)
    1. VU University medical center, Netherlands
      1. I Visman (i.visman{at}janvanbreemen.nl)
      1. Jan van Breemen Institute, Netherlands
        1. M Heierman (secr.reumatologie{at}vumc.nl)
        1. VU University medical center, Netherlands
          1. M Boers (m.boers{at}vumc.nl)
          1. VUmc, Netherlands
            1. B AC Dijkmans (bac.dijkmans{at}vumc.nl)
            1. VU University medical center, Netherlands
              1. W F Lems (wf.lems{at}vumc.nl)
              1. VU University medical center, Netherlands

                Abstract

                Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) frequently cause gastrointestinal (GI) ulcers and complications of ulcers. In 1997, in Amsterdam, the incidence of symptomatic GI events was 2.1% (95% C.I. 1.0-3.1) in patients with rheumatoid arthritis (RA). We conducted a second prospective, observational study on the symptomatic GI events in our outpatient clinics, and compared the data to our first study. At the same time a decline of GI events over the last decade was reported for US patients.

                Methods: In 2003, three questionnaires were sent to all RA patients in Amsterdam in 4-month intervals, addressing medication use, dyspepsia, and symptomatic GI events in the previous 4 months.

                Results: The incidence of GI events in high risk patients, defined as age ≥60 and/or history of GI event) using NSAIDs or COXIBs was 1.2% (95% C.I. 0.2-2.3) which appears to be substantially lower, than the 2.1% observed in 1997, albeit that this difference did not reach statistical significance (p=0.3). In 64% (95% C.I. 61-68) of the high risk patients, acid suppressive drugs, i.e. proton-pump inhibitors, prostaglandin analogs or high dose of H2-antagonists, were used. In 1997 this percentage was significantly lower, i.e. 49% (45-52; p<0.0001). The compliance to the Dutch guideline for prevention of NSAID related gastropathy was almost 75% with 64% of the patients used acid suppressive drugs and 11% used COXIBs.

                Conclusion: The present study reveals a decline of NSAID induced gastrointestinal events, which is similar to that observed in the US. Most likely this is due to a more strict adherence to guidelines for prevention of NSAID gastropathy, and better treatment of rheumatoid arthritis.

                • Gastrointestinal events
                • NSAID gastropathy
                • NSAIDs
                • Rheumatoid arthritis

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.